뇌혈관 연축(CVS) : 시장 전망, 역학, 경쟁 구도, 시장 예측 보고서(2025-2035년)

Cerebral Vasospasm (CVS) Market Outlook

Thelansis's "Cerebral Vasospasm (CVS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Cerebral Vasospasm treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Cerebral Vasospasm (CVS) Overview

Cerebral vasospasm (CVS) is a severe and potentially life-threatening complication of aneurysmal subarachnoid hemorrhage (aSAH), characterized by delayed narrowing of major intracranial arteries. It typically occurs between 3 to 14 days post-hemorrhage and is a major contributor to morbidity and mortality in affected patients.

The pathophysiology is driven by the breakdown of erythrocytes in the subarachnoid space, releasing oxyhemoglobin and other spasmogenic factors, which lead to depletion of nitric oxide, neuroinflammation, oxidative stress, and vascular remodeling. This cascade results in reduced cerebral blood flow, potentially progressing to delayed cerebral ischemia (DCI), a key determinant of poor neurological outcomes.

Clinically, CVS presents with new-onset neurological deficits, altered consciousness, and risk of cerebral infarction. Diagnosis requires close monitoring using transcranial Doppler (TCD) and CT angiography, with digital subtraction angiography (DSA) as the gold standard.

The current standard of care emphasizes maintenance of euvolemia and induced hypertension to optimize cerebral perfusion. Pharmacologically, nimodipine remains the cornerstone therapy due to its proven neuroprotective benefits. In refractory cases, endovascular interventions, including intra-arterial vasodilators and balloon angioplasty, are employed to restore cerebral blood flow.

Key Highlights

• CVS is a high-morbidity complication of aSAH, driven by delayed ischemia risk
• US aSAH incidence expected to increase from ~36.1K to ~39.4K (~0.9% CAGR)

Market Overview

• US market projected to grow from ~$102M to ~$170M (~5-6% CAGR)
• Growth driven by advanced critical care and endovascular interventions, with limited targeted pharmacologic innovation

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support
• As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025-2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market's trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard/report will cost USD 1,750 per country

Companies Mentioned

• Idorsia

Table of Contents

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)